Disease Landscape and Forecast Insights

Last Updated 2 October 2015 A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera)…

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying…

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…

Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of…

For Neurologists and Payers, What Opportunities Still Exist for Novel Disease-Modifying Therapies in an Increasingly Crowded Market? The relapsing-remitting multiple sclerosis (RR-MS) therapy…

How Are Payers Responding to High-Cost Therapies on Their Exchange-Based Plans? The Affordable Care Act (ACA) has expanded access to insurance coverage to millions and has reformed health…

The availability of novel disease-modifying therapies (DMTs), such as the oral DMTs Novartis’s Gilenya (fingolimod), Genzyme’s Aubagio (teriflunomide), and Biogen Idec’s Tecfidera (dimethyl…

Last Updated 23 July 2014 The market for disease-modifying multiple sclerosis (MS) therapies is in the midst of transformation: three oral agents are now available—fingolimod (Novartis/…

The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through…

LaunchTrends: Tecfidera (US) is a four-wave syndicated report series that specifically tracks the introduction of Tecfidera, the third-to-market oral disease-modifying therapy (DMT), based on…

Last Updated 1 May 2014 The market for disease-modifying multiple sclerosis (MS) therapies is in the midst of transformation: three oral agents are now available—fingolimod (Novartis/Mitsubishi…